CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Placebo plus standard preventive measuresWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug395 Hydroxychloroquine plus standard preventive measures Wiki 1.00
drug627 Placebo oral tablet Wiki 0.22
drug360 Hydroxychloroquine Wiki 0.13

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Efficacy and Safety of Hydroxychloroquine for COVID-19 Post-Exposure Prophylaxis of Healthcare Workers in the Philippine General Hospital and UP Manila National Institutes of Health: A Randomized, Double-blind, Placebo-controlled Trial

This COVID-19 pandemic warrants urgent strategies to protect people at high risk of infection, particularly the healthcare workers. Secondary prevention through post-exposure prophylaxis (PEP) and early treatment of infection are needed to prevent severe cases and cut secondary transmission. Hydroxycholoroquine (HCQ) is an inexpensive anti-malarial drug with immunomodulatory effects that are currently used as an off-label treatment for symptomatic COVID-19 patients. In vitro studies have shown that it can efficiently inhibit SARS-CoV-2 infection and has potential as a post-exposure prophylaxis drug.

NCT04364815 COVID-19 Drug: Hydroxychloroquine plus standard preventive measures Drug: Placebo plus standard preventive measures

Primary Outcomes

Description: Incidence of COVID-19 infection confirmed by RT-PCR COVID-19 test within the PEP treatment period (28 days) with or without symptoms of COVID-19 infection

Measure: Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection

Time: 30 days

Secondary Outcomes

Description: Incidence of patient self-reported COVID-19 related symptoms anytime during follow up period as measured by a standardized patient diary

Measure: Efficacy of study drug as post-exposure prophylaxis in preventing COVID-19 related symptoms (to be reported as absolute number and frequency of events)

Time: 30 days

Description: Interval from exposure to COVID-19 case Interval from first dose of study drug

Measure: Time to COVID-19 infection in patients receiving study drug (in days)

Time: 30 days

Description: Incidence of study drug discontinuation Incidence of all adverse events based on patients a) self-report using daily symptom diary and b) study physicians

Measure: Safety and tolerability of study drug (to be reported as absolute number and frequency of events)

Time: 30 days

No related HPO nodes (Using clinical trials)